Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02969863 · ClinicalTrials.gov registry record · NA

The Monitoring Study

A NA study of Type1diabetes, sponsored by Massachusetts General Hospital.

Completed
Registry status
NA
Development phase
27
Enrollment target
1
Study location

NCT02969863 is a NA study of Type1diabetes that has completed, run by Massachusetts General Hospital. The registered enrollment target is 27 participants, below the 260-participant average among 19 other Type1diabetes trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02969863, a NA study of Type1diabetes, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
NA
Development phase
27 participants
Enrollment target
1
Study location

Study Summary

To conduct an outpatient study testing two configurations of the bionic pancreas (bi-hormonal and insulin-only) with and without remote monitoring of hypoglycemia in 25 adult (≥ 18 years of age) subjects with type 1 diabetes in a random-order crossover study versus usual care with an insulin pump with and without remote monitoring of hypoglycemia.

Conditions Studied

Interventions

  • DEVICE Bihormonal Bionic Pancreas
  • DEVICE Insulin Only Bionic Pancreas
  • OTHER Monitored for Hypoglycemia
  • OTHER Not Monitored for Hypoglycemia

Study Locations (1)

Massachusetts

  • MGH Diabetes Research Center - Boston

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2017-04-01
Est. Completion 2017-12-28
Phase NA

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT02969863

The ClinicalTrials.gov registry entry for NCT02969863 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 260-participant average among 19 other Type1diabetes trials with a reported enrollment target (90% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type1diabetes appearing as the primary indexed condition, and to 4 interventions - of which Bihormonal Bionic Pancreas is the first listed.

NCT02969863 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02969863 about?

NCT02969863 is a clinical study titled "The Monitoring Study". To conduct an outpatient study testing two configurations of the bionic pancreas (bi-hormonal and insulin-only) with and without remote monitoring of hypoglycemia in 25 adult (≥ 18 years of age) subjects with type 1 diabetes in a random-order crossover study versus usual care with an insulin pump wi...

What is the current status of trial NCT02969863?

This trial is currently completed. It is a NA study. The enrollment target is 27 participants. The study started on 2017-04-01. Estimated completion is 2017-12-28.

What conditions does trial NCT02969863 study?

This clinical trial studies the following conditions: Type1diabetes.

What interventions are being tested in trial NCT02969863?

The interventions under investigation include: Bihormonal Bionic Pancreas (DEVICE), Insulin Only Bionic Pancreas (DEVICE), Monitored for Hypoglycemia (OTHER), Not Monitored for Hypoglycemia (OTHER).

Who is sponsoring clinical trial NCT02969863?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02969863 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type1diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.